Travere Therapeutics (TVTX) Competitors

Travere Therapeutics (NASDAQ:TVTX) and Axsome Therapeutics (NASDAQ:AXSM) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

Do insiders and institutionals have more ownership in TVTX or AXSM?

81.5% of Axsome Therapeutics shares are owned by institutional investors. 4.2% of Travere Therapeutics shares are owned by company insiders. Comparatively, 22.3% of Axsome Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Does the media prefer TVTX or AXSM?

In the previous week, Axsome Therapeutics had 12 more articles in the media than Travere Therapeutics. MarketBeat recorded 26 mentions for Axsome Therapeutics and 14 mentions for Travere Therapeutics. Travere Therapeutics' average media sentiment score of 1.03 beat Axsome Therapeutics' score of 0.38 indicating that Travere Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Travere Therapeutics	5 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Axsome Therapeutics	8 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Which has better valuation and earnings, TVTX or AXSM?

Axsome Therapeutics has higher revenue and earnings than Travere Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Travere Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Travere Therapeutics	$233.18M	6.97	-$321.55M	-$2.04	-8.94
Axsome Therapeutics	$385.69M	14.07	-$287.22M	-$5.07	-21.45

Do analysts rate TVTX or AXSM?

Travere Therapeutics presently has a consensus target price of $32.21, indicating a potential upside of 76.71%. Axsome Therapeutics has a consensus target price of $178.00, indicating a potential upside of 63.68%. Given Travere Therapeutics' higher possible upside, research analysts plainly believe Travere Therapeutics is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Travere Therapeutics	0 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.87
Axsome Therapeutics	0 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	3.07

Which has more volatility & risk, TVTX or AXSM?

Travere Therapeutics has a beta of 0.74, indicating that its share price is 26% less volatile than the S&P 500. Comparatively, Axsome Therapeutics has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500.

Is TVTX or AXSM more profitable?

Axsome Therapeutics has a net margin of -49.88% compared to Travere Therapeutics' net margin of -50.64%. Axsome Therapeutics' return on equity of -283.22% beat Travere Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Travere Therapeutics	-50.64%	-717.68%	-30.69%
Axsome Therapeutics	-49.88%	-283.22%	-33.06%

Summary

Axsome Therapeutics beats Travere Therapeutics on 11 of the 17 factors compared between the two stocks.